Imagine battling two deadly diseases at once, only to find out that even after treatment, your body's defense system is still reeling from the fight. That's the harsh reality for many individuals co-infected with Tuberculosis (TB) and HIV. Even after receiving the best available treatment, their immune systems remain in a state of dysfunction, leaving them vulnerable to future infections. But here's where it gets controversial... what if the treatments themselves, while effectively targeting the virus and bacteria, are inadvertently hindering the immune system's recovery?
A groundbreaking study from the Texas Biomedical Research Institute, published in Nature Communications, sheds light on this critical issue. Researchers discovered that the immune system remains significantly compromised – exhibiting both overactivation and impaired functionality – even after patients receive the international gold standard treatment for latent TB and HIV.
"The good news is that the treatments control the virus and kill most of the TB bacteria," explains Dr. Riti Sharan, Assistant Professor at Texas Biomed and co-corresponding author of the study. "The bad news is that the immune system in the lungs does not fully recover." Think of it like winning a war but leaving your city in ruins – you've defeated the enemy, but rebuilding is a whole other challenge.
This study is considered the most comprehensive analysis to date, detailing the aftermath of standard co-infection treatment on the lungs. The researchers were able to achieve this level of detail by utilizing well-established nonhuman primate models that closely mimic the conditions of humans with latent TB and active HIV. And this is the part most people miss... these models allow scientists to examine the intricate details of immune responses in a way that isn't possible in human studies, providing invaluable insights into the underlying mechanisms.
"We believe this is the first time researchers have shown experimentally how immune responses remain dysfunctional following co-infection and combined treatment," says Dr. Deepak Kaushal, Professor at Texas Biomed and co-corresponding author. "It's been hypothesized by many, and this is really the first deep dive into it." Essentially, while doctors suspected this was happening, this research provides concrete evidence to back up those suspicions.
Double Trouble: Understanding TB and HIV Co-infection
Latent TB occurs when Mycobacterium tuberculosis (Mtb) is present in the body but doesn't cause active disease and isn't contagious. It's estimated that a staggering quarter of the world's population – over 2 billion people – harbors latent TB. In the U.S. alone, approximately 13 million people are infected. While most remain healthy, individuals with weakened immune systems, such as those living with HIV, malnutrition, or diabetes, face a significantly higher risk of developing active TB. While antiretroviral therapy has transformed HIV from a death sentence into a manageable condition, TB has tragically emerged as the leading cause of death among co-infected individuals.
Upon an HIV diagnosis, the World Health Organization recommends antiretroviral therapy to manage the virus, alongside a preventive antibacterial regimen called 3HP. This involves taking one pill once a week for 12 weeks to minimize the risk of latent TB reactivation. The Texas Biomed team previously demonstrated that immune responses remain dysregulated even after HIV treatment alone. This time, they investigated simultaneous treatment for HIV and latent TB to determine if it could improve the restoration of immune system function in the lungs.
"Co-infection messes things up for the immune response," Dr. Kaushal explains. "You would think that after treatment the immune responses would reset to normal – that does not happen. That has the potential to explain why co-infected people remain at greater risk for respiratory infections." It highlights how the combined assault on the immune system from both diseases can have long-lasting and detrimental consequences.
Single-Cell Deep Dive: Unraveling the Immune System's Response
The research team discovered imbalances in specific populations of T cells – white blood cells that play a crucial role in the immune system – following treatment compared to a control group. Specifically, they observed a significant decrease in CD4+ effector memory T cells, which act as frontline defenders and send early warning signals to other immune cells. Furthermore, a beneficial subset of T helper cells (TH1) was reduced, while another T cell type (TH17) was elevated, potentially contributing to ongoing immune system activation.
"When the immune system is continuously activated, it leads to immune exhaustion, which increases susceptibility to reinfection with TB bacteria," Dr. Sharan emphasizes. Imagine your immune system constantly running at full speed – eventually, it's going to burn out and become less effective.
Using single-cell RNA sequencing, the team also tracked the activity of macrophages – large immune cells responsible for engulfing Mtb in the lungs – from the early stages of infection. Macrophage functionality, determined by which genes were switched on or off, underwent changes as early as two weeks after co-infection with SIV (the nonhuman primate equivalent of HIV) and crucially, these changes persisted even after the completion of treatment.
More Therapies Needed: A Call for Innovation
Based on these findings, the conclusion is clear: current treatments aren't enough. "We need host-directed therapies," Dr. Sharan argues. "The immune system is not getting any help with these standard treatments. We are controlling the bug, but what about the immune system?" Host-directed therapies, also known as immunotherapies, specifically target components of the immune system to enhance its response to treatment. The researchers are actively exploring potential options within their respective labs.
"It's clear treating TB and HIV is not going to be enough to ensure people are able to go on living healthy lives," Dr. Kaushal concludes. "Developing host-directed therapies to restore the immune system could potentially be used not just for TB and HIV, but for a range of respiratory diseases." This opens the door to a new era of treatment strategies that focus not only on eradicating the pathogens but also on revitalizing the body's natural defenses. But here's the burning question: Is it ethical to prioritize host-directed therapies when access to existing treatments for TB and HIV remains a challenge in many parts of the world? Should resources be focused on improving access to current treatments before investing in new, potentially more expensive, therapies? What are your thoughts? Share your opinions in the comments below!
